Bethany Lambright Martin

Array ( [id] => 14746853 [patent_doc_number] => 20190256600 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-22 [patent_title] => ANTIBODIES DIRECTED AGAINST PROGRAMMED DEATH- 1 (PD-1) [patent_app_type] => utility [patent_app_number] => 16/346485 [patent_app_country] => US [patent_app_date] => 2017-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15101 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -53 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16346485 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14712479 [patent_doc_number] => 20190247303 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => INHALABLE POWDER COMPOSITION COMPRISING IL-13 ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/346051 [patent_app_country] => US [patent_app_date] => 2017-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16671 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -77 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16346051 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13297659 [patent_doc_number] => 20180200366 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-19 [patent_title] => MULTIMERIC IL-15-BASED MOLECULES [patent_app_type] => utility [patent_app_number] => 15/789985 [patent_app_country] => US [patent_app_date] => 2017-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32163 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15789985 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16590583 [patent_doc_number] => 10899833 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-26 [patent_title] => Human antibody specific for interleukin-1 alpha [patent_app_type] => utility [patent_app_number] => 15/789774 [patent_app_country] => US [patent_app_date] => 2017-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7026 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15789774 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15227665 [patent_doc_number] => 10501543 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-10 [patent_title] => IL15/IL15Ra heterodimeric Fc-fusion proteins [patent_app_type] => utility [patent_app_number] => 15/785401 [patent_app_country] => US [patent_app_date] => 2017-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 259 [patent_figures_cnt] => 339 [patent_no_of_words] => 33689 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15785401 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15468645 [patent_doc_number] => 10550185 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-02-04 [patent_title] => Bispecific heterodimeric fusion proteins containing IL-15-IL-15Ra Fc-fusion proteins and PD-1 antibody fragments [patent_app_type] => utility [patent_app_number] => 15/785393 [patent_app_country] => US [patent_app_date] => 2017-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 142 [patent_figures_cnt] => 219 [patent_no_of_words] => 38922 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 195 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15785393 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12158865 [patent_doc_number] => 20180030131 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-01 [patent_title] => 'Use of Reslizumab to Treat Moderate to Severe Eosinophilic Asthma' [patent_app_type] => utility [patent_app_number] => 15/783289 [patent_app_country] => US [patent_app_date] => 2017-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 19904 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15783289 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15160743 [patent_doc_number] => 10485844 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-11-26 [patent_title] => Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor [patent_app_type] => utility [patent_app_number] => 15/711815 [patent_app_country] => US [patent_app_date] => 2017-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28313 [patent_no_of_claims] => 57 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 148 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15711815 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16492399 [patent_doc_number] => 10858424 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-08 [patent_title] => Anti-IL-6 antibodies for the treatment of arthritis [patent_app_type] => utility [patent_app_number] => 15/704848 [patent_app_country] => US [patent_app_date] => 2017-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 43 [patent_no_of_words] => 82256 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 162 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15704848 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16369100 [patent_doc_number] => 10800841 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-10-13 [patent_title] => Methods of treating autoimmunity using specific anti-IL-6 antibodies [patent_app_type] => utility [patent_app_number] => 15/703414 [patent_app_country] => US [patent_app_date] => 2017-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 72864 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15703414 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12862303 [patent_doc_number] => 20180179275 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-28 [patent_title] => ANTI-CCL2 ANTIBODIES FOR TREATMENT OF SCLERODERMA [patent_app_type] => utility [patent_app_number] => 15/702206 [patent_app_country] => US [patent_app_date] => 2017-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17950 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15702206 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14624629 [patent_doc_number] => 20190225682 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-25 [patent_title] => METHOD OF TREATING LOCALIZED FIBROTIC DISORDERS USING AN IL-33/TNF BISPECIFIC ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/328979 [patent_app_country] => US [patent_app_date] => 2017-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42986 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -99 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16328979 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17697130 [patent_doc_number] => 11370841 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-28 [patent_title] => Methods of treating fibroblast growth factor 19-mediated cancers and tumors [patent_app_type] => utility [patent_app_number] => 16/327756 [patent_app_country] => US [patent_app_date] => 2017-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 65 [patent_no_of_words] => 25186 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16327756 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17035182 [patent_doc_number] => 20210252140 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-19 [patent_title] => IMMUNOSUPPRESSIVE COMPOSITION FOR USE IN TREATING IMMUNOLOGICAL DISORDERS [patent_app_type] => utility [patent_app_number] => 16/326417 [patent_app_country] => US [patent_app_date] => 2017-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15685 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16326417 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13705371 [patent_doc_number] => 20170363640 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-21 [patent_title] => BIOMARKER FOR DIAGNOSING VASCULAR DISEASES AND THE USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/673618 [patent_app_country] => US [patent_app_date] => 2017-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9492 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15673618 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14057911 [patent_doc_number] => 10233239 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-03-19 [patent_title] => Isolated host cells expressing anti-IL-6 antibodies [patent_app_type] => utility [patent_app_number] => 15/668989 [patent_app_country] => US [patent_app_date] => 2017-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 74046 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15668989 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14243911 [patent_doc_number] => 10272138 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-30 [patent_title] => Methods of generating anti-inflammatory stem cells [patent_app_type] => utility [patent_app_number] => 15/668251 [patent_app_country] => US [patent_app_date] => 2017-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 50 [patent_no_of_words] => 25108 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 122 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15668251 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17496507 [patent_doc_number] => 11285191 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-29 [patent_title] => Immunostimulatory compositions and uses therefor [patent_app_type] => utility [patent_app_number] => 16/320586 [patent_app_country] => US [patent_app_date] => 2017-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 31775 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16320586 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12030835 [patent_doc_number] => 20170320933 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-09 [patent_title] => 'CYTOKINE-BASED FUSION PROTEINS FOR TREATMENT OF IMMUNE DISORDERS' [patent_app_type] => utility [patent_app_number] => 15/658475 [patent_app_country] => US [patent_app_date] => 2017-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 33292 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15658475 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12184077 [patent_doc_number] => 20180043010 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-15 [patent_title] => 'ANTAGONISTS OF IL-6 TO RAISE ALBUMIN AND/OR LOWER CRP' [patent_app_type] => utility [patent_app_number] => 15/653226 [patent_app_country] => US [patent_app_date] => 2017-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 81 [patent_figures_cnt] => 81 [patent_no_of_words] => 125884 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15653226 [rel_patent_id] =>[rel_patent_doc_number] =>)